Nurix Therapeutics (NRIX)
(Real Time Quote from BATS)
$15.29 USD
-0.61 (-3.84%)
Updated May 16, 2024 02:10 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Brokerage Reports
Nurix Therapeutics, Inc. [NRIX]
Reports for Purchase
Showing records 1 - 15 ( 15 total )
Company: Nurix Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Nurix Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Nurix Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for NRIX 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Nurix Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Nurix Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Developing a Novel Class of Degraders With Seagen; Raising PT to $35
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Nurix Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
NX-2127 and NX-5948 Lymphoma Data; 2Q23 Financials; Lowering PT to $33
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Nurix Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Nurix Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Gilead Exercises Option For IRAK4 Degrader; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Nurix Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Numerous Catalysts in 2H23; F4Q22 Financials Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Nurix Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q22 Financials; Several Data Releases Slated by YE22; Modulating PT to $53
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Nurix Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Equity Financing Announced; F2Q22 Financial Results; Modulating PT to $54
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Nurix Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
AACR Presentation Takeaways; 1Q22 Financials; Modulating PT to $60
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Nurix Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Nurix Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Protein Degradation to Power Cancer Treatment; Initiating at Buy and $62 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Nurix Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
|